Electrolyte and pH monitoring for fluid removal processes

Information

  • Patent Grant
  • 10179198
  • Patent Number
    10,179,198
  • Date Filed
    Tuesday, August 18, 2015
    9 years ago
  • Date Issued
    Tuesday, January 15, 2019
    5 years ago
Abstract
Methods include monitoring indicators of blood pH or blood electrolyte levels during a blood fluid removal session and adjusting concentrations of pH buffers or electrolytes in dialysate or replacement fluid used during the session based on the monitored indicators. Blood fluid removal systems may employ sensors that monitor blood pH or electrolyte levels to adjust the fluid parameters during a blood fluid removal session.
Description
FIELD

The present disclosure relates generally to devices, systems and methods for monitoring indicators of electrolytes or pH in patients for which blood cleaning or fluid removal is indicated, such as patients suffering from kidney disease or heart failure.


BACKGROUND

Patients who undergo hemodialysis or other procedures that remove solutes and fluid from the blood often die of cardiac complications. Many factors may contribute to such death, including stress placed on the heart due to the increased blood fluid volume in these patients. Increased fluid concentrations and inability to remove waste products from the blood, in some cases, can also contribute to electrolyte and pH imbalance that can affect cardiac contractility and efficiency. Further, rapid changes in fluid volume or pH or electrolyte concentration of the blood during hemodialysis or other fluid removal processes may place additional stress on the heart and may contribute to the high rate of morbidity for patients who undergo blood fluid removal procedures.


When a patient reaches a point where routine blood fluid removal procedures are prescribed, the patient undergoes periodic examinations that allow a healthcare provider to set various parameters of the blood fluid removal procedures, such as the profile of fluid removal, the composition of dialysate or replacement fluid employed, and the like. These examinations typically occur once a month in accordance with current standards of care.


Hemodialysis or similar procedures may occur three to four times a week. Thus, the patient may undergo 10 to 15 or more blood fluid removal sessions before the prescription or parameters are changed. It is possible, for example, that a prescription with regard to a dialysate electrolyte and pH buffer composition will not be appropriate for a patient several days or weeks after the prescription is set. Accordingly, it may be desirable to more frequently determine whether the electrolyte or pH concentration of a fluid used in blood fluid removal sessions is appropriate. In addition, it may be desirable to adjust the concentration or composition of the fluid during a blood fluid removal session in a manner that may improve patient health and reduce morbidity.


SUMMARY

This disclosure, among other things, describes devices, systems and methods for monitoring indicators of pH or electrolytes in patients for which blood fluid removal sessions are indicated. The monitoring may occur during a blood fluid removal session, and the concentration or composition of buffer or electrolytes may be adjusted based on monitored data acquired during the blood fluid removal session. By monitoring pH or electrolytes, the dialysate of replacement fluid may be adjusted during a session to enhance patient safety.


In various embodiments described herein, a method includes initiating a blood fluid removal procedure for a patient in need thereof. The procedure includes use of a fluid selected from a dialysate fluid or a replacement fluid. The fluid has an initial pH buffer composition or electrolyte composition. The method further includes monitoring an indicator of blood electrolyte concentration or blood pH of the patient during the blood fluid removal session, and adjusting the pH buffer composition or the electrolyte composition of the fluid based on a value of the monitored indicator. The monitoring may be of blood before or after the blood has passed through the blood fluid removal device, or may be of fluid removed from the blood. In some embodiments, data acquired from monitoring performed on blood before and after passing through the blood fluid removal device is compared to data acquired from fluid (e.g., dialysate) before and after passing through blood fluid removal media of the device, and based on the comparison, the pH buffer composition or the electrolyte composition of the fluid is adjusted.


In embodiments, a system includes a blood fluid removal device, which has (i) an inlet for receiving blood from a patient, (ii) an outlet for returning blood from the patient, (iii) a medium for removing fluid and contaminants from the blood, the medium being positioned between the inlet and the first outlet, and (iv) a fluid source for carrying a fluid, where the fluid is selected from dialysate and replacement fluid. If the fluid is dialysate, the fluid source carries the fluid to the medium. If the fluid is replacement fluid, the fluid source carries the fluid to the blood after the blood exits the medium. The system further includes (i) a concentrate source for housing a concentrate solution comprising concentrated electrolyte or pH buffer, (ii) a concentrate flow control element for controlling the rate that the concentrate solution enters the fluid source; (iii) a sensor for monitoring an indicator of blood pH or blood electrolyte concentration; and (iv) control electronics in operable communication with the sensor and the concentrate flow control element. The control electronics are configured, via the concentrate flow control element, to adjust the rate at which the concentrate solution enters the fluid source based on data obtained from the sensor.


In embodiments, a system includes (i) a medium housing defining a major chamber; (ii) a blood flow removal membrane disposed in the housing and sealingly dividing the major chamber into first and second minor chambers; (iii) a first inlet and a first outlet in fluid communication with the first minor chamber, wherein the system is configured such that blood enters the first minor chamber through the first inlet and exits the first minor chamber through the first outlet; (iv) a second inlet and a second outlet in fluid communication with the second minor chamber, wherein the system is configured such that dialysate enters the second minor chamber through the second inlet and exits the second minor chamber through the second outlet; (vi) a dialysate regeneration medium in fluid communication with and disposed in a dialysate flow path between the second inlet and the second outlet; (vii) a concentrate source for housing a concentrate solution comprising concentrated electrolyte or pH buffer; (viii) a concentrate flow control element for controlling the rate that the concentrate solution enters the dialysate flow path downstream of the dialysate regeneration medium and upstream of the second inlet; (ix) a sensor configured to monitor an indicator of electrolyte concentration or pH of dialysate in the dialysate flow path downstream of the dialysate regeneration medium and upstream of the second inlet; and (x) control electronics in operable communication with the sensor and the concentrate flow control element, wherein the control electronics are configured, via the concentrate flow control element, to adjust the rate at which the concentrate solution enters the dialysate flow path based on data obtained from the sensor.


In any embodiment, the system can comprise a blood fluid removal device comprising: (a) an inlet for receiving blood from a patient; (b) an outlet for returning blood from the patient; (c) a medium for removing fluid and contaminants from the blood, the medium being positioned between the inlet and the outlet, and (d) a fluid source for carrying fluid to the medium; and the system can further comprise a concentrate source for housing a concentrate solution comprising concentrated electrolyte or pH buffer; a concentrate flow control element for controlling the rate that the concentrate solution enters the fluid source; a first sensor configured to monitor an indicator of electrolyte concentration or pH in dialysate in the fluid source before the dialysate enters the medium; a second sensor configured to monitor an indicator of electrolyte concentration or pH in the dialysate in the fluid source after the dialysate exits the medium; and control electronics in operable communication with the first sensor and the concentrate flow control element, wherein the control electronics are configured, via the concentrate flow control element, to adjust the rate at which the concentrate solution enters the fluid source based on data obtained from the first sensor and the second sensor.


In any embodiment, the data obtained from the first sensor and the second sensor can be used to predict blood electrolyte concentration or blood pH.


In any embodiment, the control electronics can be configured, via the concentrate flow control element, to adjust the rate at which the concentrate solution enters the fluid source based on a comparison of the data received from the first sensor and the data received from the second sensor.


In any embodiment, the system can comprise a dialysate regeneration system, wherein the first sensor is configured to monitor the indicator of electrolyte concentration or pH in the dialysate in the fluid source after the dialysate exits the regeneration system, and wherein the second sensor is configured to monitor the indicator of electrolyte concentration or pH in the dialysate in the fluid source before the dialysate enters the regeneration system.


In any embodiment, the concentrate solution can enter the fluid source after the dialysate exits the dialysate regeneration system.


In any embodiment, the first sensor can be configured to monitor the indicator of electrolyte concentration or pH in the dialysate in the fluid source after the concentrate solution enters the fluid source.


In any embodiment, the system can comprise a third sensor configured to monitor the indicator in the blood after the blood exits the medium.


In any embodiment, the control electronics can be configured to adjust a rate at which dialysate enters the medium or the rate at which blood enters the medium based on data obtained from the first sensor and the second sensor.


In any embodiment, the control electronics, or components thereof, can be housed within a housing of the blood fluid removal device.


In any embodiment, a method can comprise initiating a blood fluid removal procedure, wherein the procedure comprises use of a dialysate with an initial pH buffer composition or electrolyte composition; monitoring an indicator of pH or electrolyte concentration in the dialysate during the blood fluid removal session; and adjusting the pH buffer composition or the electrolyte composition of the dialysate based on a value of the monitored indicator.


In any embodiment, the indicator of pH or electrolyte concentration in the dialysate can be monitored after the dialysate exits a blood fluid removal medium and the indicator of pH or electrolyte concentration in the dialysate can be monitored before the dialysate enters the blood fluid removal medium.


In any embodiment, the pH buffer composition or electrolyte composition of the dialysate can be adjusted based on a comparison of the pH or electrolyte concentration before the dialysate enters the medium and after the dialysate exits the medium.


In any embodiment, adjusting the pH buffer composition or electrolyte composition can comprise adding a concentrate electrolyte solution or concentrated buffer solution to the dialysate.


In any embodiment, the method can comprise determining whether a value of the monitored indicator crosses a threshold; and providing an alert if the value of the monitored indicator crosses the threshold.


In any embodiment, the method can comprise deriving a blood electrolyte concentration or blood pH from the monitored indicator before the dialysate enters the medium and after the dialysate exits the medium.


In any embodiment, the method can comprise monitoring the indicator in blood after the blood exits the blood fluid removal medium.


In any embodiment, the method can comprise adjusting a rate at which dialysate enters the blood fluid removal medium or a rate at which blood enters the blood fluid removal medium based on the monitored indicator.


In any embodiment, the dialysate can be regenerated with a dialysate regeneration system, and the indicator of pH or electrolyte concentration in the dialysate can be monitored after the dialysate exits the blood fluid removal medium but before the dialysate enters the dialysate regeneration system; and the indicator of pH or electrolyte concentration in the dialysate can be monitored after the dialysate exits the dialysate regeneration system but before the dialysate enters the blood fluid removal medium.


In any embodiment, adjusting the pH buffer composition or electrolyte composition can comprise adding a concentrated electrolyte solution or concentrated buffer solution to the dialysate after the dialysate has been regenerated.


In any embodiment, the pH or electrolyte concentration in the dialysate can be monitored after the concentrated electrolyte solution or concentrated buffer solution has been added to the dialysate.


One or more embodiments of the systems, devices and methods described herein may provide one or more advantages over prior systems, devices and methods for blood fluid removal in patients. Such advantages will be apparent to those skilled in the art upon reading the following detailed description.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated into and form a part of the specification, illustrate several embodiments of the present disclosure and, together with the description, serve to explain the principles of the disclosure. The drawings are only for the purpose of illustrating embodiments of the disclosure and are not to be construed as limiting the disclosure.



FIGS. 1-3 are schematic block diagrams showing interaction of blood fluid removal devices with a patient showing flow of blood (dashed arrows) and fluid (solid arrows), which blood fluid removal devices may be used in various embodiments described herein.



FIG. 4 is a schematic block diagram showing some selected components of an embodiment of a sensor device.



FIGS. 5-6 are schematic block diagrams showing sensors and blood flow between patients and a blood fluid removal devices.



FIGS. 7-8 are schematic block diagrams showing flow paths and some control mechanisms (closed loop: FIG. 7; open loop: FIG. 8) for controlling flow of concentrate into fluid for use in a blood fluid removal process based on monitored pH or electrolytes.



FIGS. 9-10 are schematic block diagrams of some components of blood fluid removal devices that are configured to adjust pH or electrolyte concentrations of fluids in response to data regarding monitored pH or electrolyte levels in blood.



FIGS. 11-13 are flow diagrams illustrating overviews of general methods in accordance with embodiments described herein.





The schematic drawings presented herein are not necessarily to scale. Like numbers used in the figures refer to like components, steps and the like. However, it will be understood that the use of a number to refer to a component in a given figure is not intended to limit the component in another figure labeled with the same number. In addition, the use of different numbers to refer to components is not intended to indicate that the different numbered components cannot be the same or similar.


DETAILED DESCRIPTION

In the following detailed description, reference is made to the accompanying drawings that form a part hereof, and in which are shown by way of illustration several embodiments of devices, systems and methods. It is to be understood that other embodiments are contemplated and may be made without departing from the scope or spirit of the present disclosure. The following detailed description, therefore, is not to be taken in a limiting sense.


All scientific and technical terms used herein have meanings commonly used in the art unless otherwise specified. The definitions provided herein are to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.


As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” encompass embodiments having plural referents, unless the content clearly dictates otherwise.


As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.


As used herein, “have”, “having”, “include”, “including”, “comprise”, “comprising” or the like are used in their open ended sense, and generally mean “including, but not limited to.”


As used herein, a “patient for which a blood fluid removal session is indicated” is a patient that has undergone, is undergoing, or is likely to undergo at least one blood fluid removal session. In general, such patients are fluid overloaded patients, such as patients suffering from heart failure, chronic kidney disease, or acute kidney failure. Often such patients are stage 3 to stage 5 chronic kidney disease patients, are unresponsive or under-responsive to diuretics, or the like.


As used herein, a “blood fluid removal process,” or the like, refers to a process from which fluid is removed from blood of a patient and the blood is returned to the patient. In most cases, the blood is also cleaned; i.e., waste products are removed from the blood and cleaned blood is returned to the patient. Examples of blood fluid removal processes include ultrafiltration, hemofiltration, hemodialysis, hemodiafiltration, peritoneal dialysis, and the like. Any patient for which blood fluid removal is indicated may benefit from the devices, systems and methods described herein.


This disclosure relates to, among other things, systems and methods for monitoring indicators of pH or electrolyte concentrations in patients for which a blood fluid removal process is indicated. In embodiments, the sensors are configured and positioned to monitor pH or electrolytes in one or more of (i) blood of the patient before the blood enters a fluid removal or cleaning medium of the blood fluid removal device; (ii) blood of the patient before after blood exits the medium before being returned to the patient; (iii) fluid removed from the blood of the patient after passing through the medium; (iv) fluid, such as dialysate, before entering the medium; (v) fluid upstream or downstream of the addition of a concentrate for use in altering the composition of the fluid (e.g., dialysate or replacement fluid); (vi) or the like. Additional discussion with regard to sensor placement and use of such sensors will follow. First, however, a brief discussion of blood fluid removal devices or systems that may be used in accordance with the teachings presented herein is presented.


Any suitable device or system for removing fluid, or fluid and contaminants, from blood may be used in accordance with the teachings presented herein. The devices, or components thereof, may be traditional large counsel-type, wearable, or implantable.


Block diagrams of some example devices and systems are shown in FIGS. 1-3. As shown in FIG. 1, blood may be removed from a patient 10 and fluid may be removed via a blood fluid removal device 100 and returned to the patient 10. Removed fluid may be diverted. In some embodiments where the blood fluid removal device 100 or system, or components thereof, are implanted, the removed fluid may be diverted to the patient's bladder. Examples of blood fluid removal devices 100 that may operate as depicted in FIG. 1 are ultrafiltration and hemofiltration devices. Examples of such devices and components thereof that may be employed in accordance with the teachings presented herein are well known in the art. It will be understood that peritoneal dialysis, where dialysate is introduced into the peritoneal cavity, may also be employed.


With some of such devices, replacement fluid may be introduced into the patient's blood if fluid is removed from the blood by the device 100 at too great of a rate or amount. The replacement fluid may be added to the original blood before fluid removal or may be added to the blood after initial fluid removal and prior to return to the patient's cardiovascular system. Preferably, the replacement fluid is added after initial fluid removal. The pH and electrolyte concentration of the replacement fluid may be set or adjusted, e.g. as described in more detail below, based on monitoring of pH or electrolytes of the patient.


As shown in the embodiment depicted in FIG. 2, the blood fluid removal device 100 may employ dialysate to assist in removal of contaminants from the patient's blood and in maintaining proper pH and electrolyte balance. The pH or electrolyte concentration of the dialysate may be set or adjusted, e.g. as described in more detail below, based on monitoring of pH or electrolytes. Used dialysate and fluid removed from the blood may be diverted. In some embodiments, particularly where the blood fluid removal device 100 or system or components thereof are wearable or implantable, the used dialysate and removed fluid, or a portion thereof, may be regenerated (indicated by dashed lined regeneration system 150) to produce fresh dialysate for re-use in the blood fluid removal process. One system for regeneration of dialysate is the REDY system, such as described in Roberts, M, “The regenerative dialysis (REDY) sorbent system,” Nephrology 4:275-278, 1998, which system may be employed or readily modified for use in embodiments described herein. As shown in FIG. 2, a concentrate may be added to the regenerated dialysate to adjust the pH and electrolytes of the regenerated dialysate to an amount suitable for re-use as fresh dialysate.


Regardless of whether the dialysate is regenerated, systems and devices that operate in a manner shown in the embodiment of FIG. 2 include hemodialysis and hemodiafiltration systems. Examples of such devices and components thereof that may be employed in accordance with the teachings presented herein are well known in the art. It will be understood that peritoneal dialysis, where the dialysate is introduced into peritoneal cavity may also be employed.


As shown in FIG. 3, in cases where the blood fluid removal device 100 of FIG. 2 removes fluid from the blood at too high of a rate, replacement fluid may be introduced into the patient's blood, upstream or downstream of fluid removal, e.g. as described above with regard to FIG. 1.


Regardless of the device or blood fluid removal process employed, it is important to ensure that the blood pH and electrolyte concentrations are within suitable ranges. If blood electrolyte concentrations are not within suitable ranges, problems with cardiac contractility, efficiency and the like may occur. If the pH is not within a suitable range, acidosis may result, which can result in disruption of cell membranes and denaturation of proteins. In either case, if ranges of blood electrolytes and pH are not properly controlled, the patient's health may be at risk. For example, sudden and cardiac death (including death from congestive heart failure, myocardial infarction, and sudden death) are common in hemodialysis patients. See Bleyer et al, “Sudden and cardiac death rated in hemodialysis patients,” Kidney International, (1999), 55:1552-1559.


Accordingly, one goal of hemodialysis, ultrafiltration, and the like is to ensure that the patient's blood pH and electrolyte concentrations are within acceptable ranges. Typical ranges of pH and blood electrolyte concentration that are desired during or following a blood fluid removal session are provided in Table 1 below. As indicated in Table 1, concentrations of various acids or bases (or salts or hydrates thereof) are often important in determining the pH of blood. Accordingly, some typical target concentrations of such acids, bases are presented in Table 1.









TABLE 1







Typical target ranges for pH and electrolytes


(ref. Medical Surgical Nursing, 7th Ed., 2007)









Target Range














pH
7.35-7.45











Phosphate
2.8-4.5
mg/dL



Bicarbonate
22-26
mEq/L



Cl
96-106
mEq/L



Mg2+
1.5-2.5
mEq/L



Na+
135-145
mEq/L



K+
3.5-5.0
mEq/L



Ca2+
4.5-5.5
mEq/L










However, it will be understood that the target for a particular patient may be different from the values presented in Table 1 for one or more electrolyte or pH. It will also be understood that buffers are typically employed to maintain proper blood pH.


Some suitable buffers that may be used in fluid, such as replacement fluid or dialysate, include bicarbonate, acetate, citrate, lactate, amino acid and protein buffers. The concentration and composition of the buffers and components thereof may be adjusted based on monitored pH of the patient's blood. Similarly, the concentration of electrolytes such as sodium, potassium, calcium, and chloride in replacement fluid or dialysate may be set or altered based the monitored levels of electrolytes.


Any suitable sensor may be employed to monitor pH or electrolytes. For example and referring to FIG. 4, a block diagram showing some components that a sensing device 200 may include is depicted. The sensing device 200 is shown as a stand-alone device in FIG. 4, but is will be understood that the device, one or more components thereof, may be incorporated into other devices, such as a blood fluid cleaning device. The sensor 200 depicted in FIG. 4 has a housing 299 (which can be shared with another device if the sensor, or portion thereof, is incorporated into the other device) for containing various electronic components 296, 297, 289, 295. Sensing circuitry 296, such as analog-to-digital convertor, band-pass filter, or the like, is operably coupled to power supply 297 (which, again may be shared) and control electronics 295 (which may be shared), which include a processor 294 and a memory 293 for storing sensed data and processor instructions. Sensing circuitry 296 is also operably coupled to transducer 205, such as an ion selective electrode, via lead 207. In some embodiments (not shown), the device 200 is leadless, and the transducer 207 or ion selective electrode is exposed through housing 299. Control electronics 295 are operably coupled to power supply 297 and to communication circuitry 289 for communicating with another device external. In cases where the sensor 200 is a stand-alone device, communication circuitry may be used to communicate with a blood fluid removal device or a device in communication with a blood fluid removal device to transmit data acquired from the sensor to the blood fluid removal device.


Any suitable transducer may be employed to detect pH or electrolytes. In embodiments, the transducer is an ion selective electrode configured to detect H+ ions, K+ ions, Na+ ions, Ca2+ ions, Cl ions, phosphate ions, magnesium ions, acetate ions, amino acids ions, or the like. Such electrodes, and components of sensors employing such electrodes, are known in the art and may be employed, or modified to be employed, for use in the monitoring described herein.


In some embodiments, one or more sensors are employed to detect one or more ions to gauge pH or electrolytes in the blood. In some embodiments, a sensor may have more than one transducer, even if leadless, that may monitor more than one ionic species. By measuring more than one ionic species, a more detailed understanding of the levels of various electrolytes or blood components may be had. For example, in some patients in some situations, one electrolyte may be at elevated levels while another may be at reduced levels. In some embodiments, more than one sensor for the same ion is employed for purposes of result confirmation and redundancy, which can improve reliability and accuracy. In some embodiments, sensors for the same ion may be configured to accurately detect different ranges of concentrations of the ion. In embodiments, more than one transducer is present in a single unit. This allows for convenient data collection and circuitry, as all the data may be collected in one place at the same time. Further, the multiple transducers may share the same fluid collection mechanism (e.g., a microdialyzer in the case of an implant), and if needed or desired, may share the same data processing and memory storage components.


A sensor (or transducer) may be placed at any suitable location for purposes of monitoring electrolytes or pH. For example, and with reference to FIG. 5, an example of a blood fluid removal system and sensors is depicted. One or more of sensors 200A, 200B may be employed. As shown in FIG. 5, a pH or electrolyte sensor 200A may be located external to the patient 10 and configured to monitor pH or electrolyte levels in the blood before the blood enters the blood fluid removal device 100 (or before entering blood fluid removal medium, as will be discussed below in more detail). For example, sensor 200A may be positioned such that a transducer is placed within a catheter carrying blood from the patient 10 to the blood fluid removal device 100 or blood fluid removal media.


Data acquired from a sensor 200A upstream of the fluid delivery device 100 or blood fluid removal media provides an indication of the actual status of the patient 10. As a blood fluid cleaning session progresses, data acquired from a sensor 200A upstream of the fluid delivery device 100 or medium can be used to determine whether blood pH and electrolytes are approaching target ranges or to determine the rate at which pH and electrolytes are changing in the patient as a result of the blood fluid removal process. While not intending to be bound by theory, it is possible that too rapid of a change in pH or electrolyte concentrations can lead to patient hypotension or sudden death that is seen in patient populations that undergo blood fluid removal processes. By monitoring and controlling the rate of change of pH or electrolyte changes in the blood of a patient during the blood fluid removal session, perhaps the incidence of crashing or sudden death can be reduced.


In some embodiments, a sensor 200B is located external to the patient 10 and configured to monitor pH or electrolyte levels in the blood after the blood exits the blood fluid removal device 100 (or after exiting the blood fluid removal medium) and before being returned to the patient 10. For example, sensor 200B may be positioned such that a transducer is placed within a catheter carrying blood from the blood fluid removal device 100 (or medium) to the patient 10. Such a downstream sensor 200B may be used to ensure that pH and electrolyte levels of blood to be returned to the patient are not out of range. If the detected levels are out of range or are tending towards out of range, adjustments to pH and electrolyte concentrations can be made to fluid (dialysate or replacement fluid) to avoid introducing fluid into the patient 10 that may cause or exacerbate a cardiac problem associated with electrolyte or pH levels that are too high or too low.


In some embodiments, the system employs both an upstream sensor 200A and a downstream sensor 200B. With such systems, the pH or electrolyte levels detected upstream and downstream may be compared, and the compared data may be used to adjust the pH or electrolyte concentration or composition of fluid employed during a blood fluid removal session. The compared data may also be used to determine the rate of change of blood electrolyte concentration or pH. By way of example, prior to a blood fluid removal session or in the early parts of such a session, the patient is typically fluid over-loaded and the concentration of electrolytes may be low (due to the increased fluid volume). It may be appropriate to allow a slightly higher than target concentration electrolyte to be introduced back into the patient when the patient's electrolyte levels are low. However, as the patient's electrolyte levels (as measured by upstream sensor 200A) approach target levels, the electrolyte levels in the returned blood (as measured by downstream sensor 200B) should within target range. Monitoring both upstream and downstream will allow for adjustments and checks on progress that may not be attainable by monitoring only one or the other.


Referring now to FIG. 6, a system employing sensors 200B, 200C, 200D, 200E in alternative or additional locations is shown. Any one or more of such sensors 200B, 200C, 200D, 200E may be employed. The system may also employ one or more downstream sensors as described with regard to FIG. 5, but are not shown in FIG. 6. A brief discussion of some possible configurations and uses of sensors 200B, 200C, 200D, 200E is provided herein. However, it will be understood that meaningful data may be obtained from configurations other than those described below.


In embodiments, the system (e.g., the system depicted in FIG. 6) employs two upstream sensors 200B, 200C. The first upstream sensor 200B is positioned to monitor pH or electrolyte levels in the blood after it exits the blood fluid removal device 100 or medium but before replacement fluid is added. The second sensor 200C is positioned to monitor pH or electrolyte levels of the blood after the replacement fluid is added and before the blood is returned to the patient 10. The first sensor 200B may be used to determine what adjustments may be needed to pH and electrolyte levels, and the second sensor 200C may be used to verify that the appropriate adjustments were made to achieve the desired pH and electrolyte concentrations prior to returning the blood to the patient.


In embodiments, the system employs a sensor 200E to monitor pH or electrolytes removed from the blood of the patient after exiting the blood fluid removal device 100 or medium, and may include a sensor 200D configured and positioned to monitor pH or electrolytes of fluid (in the depicted case, dialysate) prior to entering the blood fluid device 100 or medium. By monitoring the pH or electrolytes in the fluid as it leaves the device 100 or medium (or the differential pH or electrolyte levels from before entering the device or medium and after exiting the device or medium), the pH or levels of electrolytes (or change in pH or electrolytes) exiting the device 100 or medium may be used to predict the blood pH and electrolyte levels without having to measure the levels in the blood directly. In cases where pH or electrolytes are detected in fluid other than blood and used to derive or predict pH or electrolyte levels or changes in blood, such detection serves as an “indicator” of blood pH or electrolytes. Of course, direct detection in blood also serves as an indicator of blood pH or electrolytes.


Regardless of which sensors 200A-E (see, FIGS. 4-6) are employed, data acquired from the sensors may be used to adjust the pH or electrolyte concentrations of fluid (e.g. dialysate or replacement fluid) used during the dialysis session. In some embodiments, the concentrations of dialysate or replacement fluid are varied and the patient's response to the varying concentrations, as measured by one or more of sensors, is used to determine how best to proceed with further adjustments. In essence, the system may be configured to learn what works best for the particular patient 10. For example, dialysate or replacement fluid having different buffer concentrations or compositions or different electrolyte concentrations may be used during an initial blood fluid session or early in a blood fluid session. The patient's response to these different fluids can be monitored via sensors, and the system can learn what works best for the patient. For example, the system can determine whether the use of the different fluids resulted in the patient's blood levels approaching target levels or deviating from target levels, as well as the rate at which the levels approach or deviate from target ranges. Based on the initial sessions or stages, the system may begin to predict how to react to a particular monitored pH or electrolyte level for the patient and adjust the fluid pH and electrolyte concentrations accordingly.


The pH and electrolyte concentration of the fluid (dialysate or replacement fluid) may be adjusted in any suitable manner. For example and with reference to FIGS. 7-8, some representative components of an example of a closed-loop system (FIG. 7) and an open-loop system (FIG. 8) for adjusting pH and electrolyte concentrations of fluid are shown. With reference to FIG. 7, data from one or more sensor 200 is presented to control electronics 495, which are configured to control flow control elements 415, 425, 435, such as valves. The electronically controllable flow control elements 415, 425, 435 are in fluid communication with supplies of concentrated electrolyte or buffer solutions 410, 420, 430 and with fluid line 440, which may be a catheter for carrying fresh dialysate or a catheter for carrying replacement fluid. The electronically controllable flow control elements 415, 425, 435, via control electronics 495, control the rate at which the concentrates 410, 420, 430 flow into the fluid line 440. The concentrates 410, 420, 430 are added to bulk fluid 400 to adjust the concentration of electrolytes or the pH of the bulk fluid (and thus the blood).


Referring now to FIG. 8, data from one or more sensor 200 may be processed and appropriate information presented on a display 600, which may be a part of the blood fluid removal device, a separate computer, or the like. A healthcare provider may use the information presented on the display 600 to adjust the concentration of electrolytes or pH. This can be done, for example, by transmitting appropriate instructions to the control electronics via an input device 500. Any suitable input device 500 may be used. For example, input device 500 may be a keyboard, a computer, a tablet, a personal data assistant, a physician programmer, or the like. In some embodiments, the input device 500 is the display 600; e.g., where the display 600 is a touch screen device. Regardless of how the instructions are input, the control electronics 495 can control flow control elements 415, 425, 435 to control the amount of concentrate 410, 420, 430 introduced to bulk fluid 400, which may be dialysate or replacement fluid.


Any number of suitable concentrates may be used. For example, one concentrate may be sufficient with higher amounts being added when the electrolytes are determined to be low in the patient's blood, and smaller amounts being added when the electrolytes are determined to be high in the patient's blood. More than one concentrate may be used when it is desired to, for example, control pH and electrolyte concentration independently or to control concentration of different electrolytes independently. In embodiments, the number of concentrates is the same as the number of ion species (pH and electrolytes) monitored.


Control elements 415, 425, 435, as depicted in FIGS. 7-8 and discussed above, may be any suitable control element, such as electronically controllable valves, electronically controllable pump mechanisms, or the like.


Any suitable system may be configured as depicted in FIGS. 7-8 to provide control of adjustment of pH or electrolytes based on data acquired from one or more sensors. By way of example, selected components of two example systems are illustrated in FIGS. 9-10. The system in FIG. 9 illustrates control of flow of a concentrate into replacement fluid, and the system in FIG. 10 illustrates control of flow of a concentrate into dialysate.


Referring now to FIG. 9, the depicted device 100 includes a fluid pathway for adding replacement fluid to blood before it is returned to the patient. The device 100 includes an inlet 110 for receiving blood from the patient and an outlet 140 for returning blood to the patient. In the flow path between the inlet 110 and outlet 140 are a blood flow control element 120 and a medium for removing fluid and contaminants from the blood. The blood flow control element 120 is operably coupled to control electronics 150 which provide instructions to control the rate at which blood is passed through medium 130. Fluids and contaminants removed from the blood by the medium 130 may exit via outlet 180.


The device 100 depicted in FIG. 9 also includes an inlet 197 for receiving bulk replacement fluid and a replacement fluid flow control element 195 in communication with the inlet and configured to control the rate at which the replacement fluid is added to the blood. The control electronics 150 are operably coupled to the replacement fluid flow control element 195 and are configured to control the rate at which replacement fluid flow control element 195 adds fluid to the blood. The device 100 also includes (i) an inlet 401 for receiving a concentrate for adjusting the pH or electrolyte concentration of the bulk replacement fluid, and (ii) a concentrate flow control element 415 in communication with the inlet 401 and configured to control the rate at which the concentrate is added to the replacement fluid or blood before the blood is returned to the patient. Preferably, the concentrate is added to the replacement fluid prior to the replacement fluid being added to the blood (as depicted) so that the concentrate may be mixed or diluted prior to being added to the blood. The device may include a mixer (not shown) to mix the concentrate and bulk replacement fluid prior to adding to the blood.


In the device depicted in FIG. 9, the control electronics 150 are operably coupled to the concentrate flow control element 415 and are configured to control the rate at which the concentrate flow control element 415 adds fluid to the replacement fluid or blood based on data received from one or more sensors 200 that monitor pH or electrolytes levels (e.g., as described above). By controlling the rate at which the concentrate is introduced into replacement fluid or blood, the concentration or pH (or buffering capacity) of the returned blood can be controlled.


Referring now to FIG. 10, in which components that are numbered the same as in FIG. 12 refer to the same or similar components, a schematic block diagram of selected components of a blood fluid removal device 100 is shown. In the embodiment depicted in FIG. 13, the device has an inlet 110 for receiving blood from a patient, a blood flow control element 120 in communication with the inlet 110 and configured to control the rate at which blood flows through medium 130 for removing fluid and contaminates from the blood. The device also includes an outlet 140 in communication with the medium 130 for returning blood to the patient. In the depicted embodiment, the medium 130 component has a housing 139 defining a major chamber 131. A semipermeable filter 135, such as a hemodialysis or hemodiafiltration membrane filter, sealingly divides the major chamber into two minor chambers 133, 137; one 133 for blood flow and the other 137 for dialysate flow (as well as fluid and waste that passes through the filter 135 from the blood)


In the embodiment depicted in FIG. 10, used dialysate is regenerated by passing through dialysate regeneration medium 402 or components, such REDY regeneration medium and components, or the like, to regenerate bulk dialysate. The device also has an outlet 180 in communication with the medium 130 for diverting fluid removed from the blood out of the device. A flow regulator element 700, such as a valve, is operably coupled to control electronics 150 and is disposed in the flow path between the medium 130 and the outlet 180 to control the amount of fluid that exits the device (as a portion of the fluid is regenerated). Often, the regeneration media or components (402) remove much of the pH buffer or electrolytes from the dialysate. Accordingly, a concentrate containing concentrated electrolytes and pH buffers is added to the regenerated dialysate before the dialysate re-enters the medium 130. In some embodiments, a sensor 299 is positioned downstream of the regeneration medium 402 to monitor a level of a component of the regenerated dialysate. The sensor 299 may be a pH or electrolyte sensor and data acquired from sensor 299 may be used in determining how much concentrate to add to the regenerated fluid (which data may be provided to control electronics 150). The sensor 299 may be a sensor that monitors a blood waste product, such as urea, to determine whether the regeneration media 402 is properly functioning. Increased or detectable levels of a waste product may indicate that the regeneration media 402 or components may need replacement or regeneration.


In the depicted embodiment, the concentrate 410 is stored in a reservoir 410, having an inlet 401 that allows the concentrate supply in the reservoir 410 to be replenished from time to time. The rate at which the concentrate is added to the regenerated dialysate is controlled by concentrate flow control element 415, which is operably coupled to control electronics 150, and is based on data received from sensor 200 that monitors pH or electrolyte concentrations (e.g., as described above).


The device 100 in FIG. 10 also has a dialysis flow control element 170 for controlling the rate at which dialysis is introduced into the dialysis flow compartment of the medium 130.


In the depicted embodiment, the device 100 also includes a negative pressure control element 190 in communication with the dialysate compartment of the medium component 130. The negative pressure control element 190, which may include a pump or the like, may be used to generate or change a pressure differential across the membrane to control the rate at which fluid is removed from blood that passes though the medium component 130.


The control electronics 150, which may include a processor, memory, etc., are operably coupled to, and configured to control, the blood flow control element 120, the dialysis flow control element 170, and the negative pressure control element 190. By controlling these elements in a coordinated manner, the rate at which fluid is removed from blood may be controlled. It will be understood that a device 100 need not have all of the controllable elements (120, 170, 190) depicted in FIG. 10 to effectively control rate of fluid removal from blood.


Any suitable control element may be used for the various control elements (120, 150, 170, 195, 415) depicted in FIGS. 9-10. For example, a variable or adjustable rate pump may be employed. Alternatively or in addition, a series of electronically controllable valves may be employed. In some embodiments, the valves are in communication flow paths having differing flow resistances.


While FIGS. 9-10 show devices that can adjust blood electrolyte or pH by adjusting the pH or electrolyte concentration of replacement fluid or dialysate, it will be understood that pH and concentration can also be adjusted by, for example, adjusting the rate at which dialysate or blood is passed over a dialysis membrane. The rate of transfer between blood and dialysate of electrolytes, etc. across the membrane will be dependent on the flow rate of the blood and the dialysate. Accordingly, in systems where dialysate electrolyte concentration or pH cannot be readily adjusted, the rate of flow of blood or dialysate flow may be altered to achieve similar effects to adjusting the concentration of electrolytes in dialysate.


While FIGS. 9-10 depict components as being within a single unit, it will be understood that one or more of the components may be housed in separate units. For example, the control electronics, or a portion thereof, may be housed in a separate device, such as a computer, tablet, physician programmer, or the like. The computer, tablet, etc. may receive input from sensors, determine appropriate action to take, and instruct appropriate components of a blood fluid removal device to take the appropriate action.


It will be understood that the blood fluid removal devices and systems, and components thereof, described herein are presented for purposes of illustration and not limitation. Components, devices and systems other than those described herein, or derivations of the components, devices and systems described herein, may be employed. Further, components of the devices depicted and discussed above may be interchanged, substituted or added to components of alternative embodiments, as appropriate. Further, it will be understood that, while many of the blood fluid removal devices depicted in a variety of the figures, such as FIGS. 1-3 and 5-6, are shown as external to the patient, the teachings presented herein apply if the device, or components thereof, were implanted in the patient.


The devices and systems described above, or components thereof, may be used to carry out the methods depicted in FIGS. 11-13 and described below, or portions thereof. Of course, any suitable device or system may be employed to carry out the methods, or portions thereof, described below. It will be understood that various steps of the methods presented with regard to any one of FIGS. 11-13 below may be interchanged, substituted, or added to steps presented with regard to any other of FIGS. 11-13.


Referring now to FIG. 11, the depicted method includes initiating a blood fluid removal session (801) and monitoring an indicator pH or electrolyte concentration of blood (810); e.g. detecting pH or electrolytes in blood or in fluid from which pH or electrolyte levels in blood can be derived. Based on the monitored indicator of pH or electrolytes, the pH or electrolyte composition or concentration of fluid (e.g., dialysate or replacement fluid) used in the blood fluid removal session may be adjusted (860). For example, based on one or more of the current value of a monitored ionic species or the rate of change in the monitored ionic species, the fluid composition may be adjusted, e.g. as discussed above.


As shown in FIG. 11, continuous, periodic or intermittent determinations may be made as to whether the pH or electrolyte concentration is out of range (830) based on data acquired during the monitoring (810). For example, a determination (830) may be made as to whether pH or electrolyte levels crossed a threshold (e.g., a ceiling or floor). If the pH or electrolytes are determined to be within range, monitoring (810) may continue. If the pH or electrolytes are determined to be out of range (e.g., cross a threshold), an alert (840) may be issued to notify the patient or a healthcare provider of the situation. In some cases, the situation may warrant stopping (890) of the blood fluid removal session; e.g., if the detected pH or electrolytes are too far out of range or cross a heightened threshold. In other cases, it may be suitable to continue with the blood fluid removal session with heightened awareness of a situation for which increased attention may be warranted.


Referring now to FIG. 12, the depicted method includes initiating a blood fluid removal session (801) and monitoring an indicator pH or electrolyte concentration upstream (815) and downstream (813) of blood fluid removal. Data acquired from upstream and downstream sensors may be compared to determine how to adjust (860) the fluid composition, e.g. as described above.


Referring now to FIG. 13, the depicted method show a method where blood electrolyte concentration or pH is adjusted by altering the flow rate of dialysate or blood. The method includes initiating a blood fluid removal session (900), such as a hemodialysis session, and monitoring an indicator of pH or electrolyte (910), which can be in the patient, upstream of the device, downstream of the device, within the device, or the like. Based on the monitored data (910), adjustments to the flow of dialysate or blood may be made (920) to adjust the electrolyte concentration or pH in the blood that gets returned to the patient.


The methods described herein, including the methods depicted in FIGS. 11-13, may be carried out by sensor devices, blood fluid removal devices, or other devices in communication with sensor devices or blood fluid removal devices. These methods may be algorithms or instructions programmed into memory of such devices, which may be carried out by processors or other control electronics of the devices. Preferably, the processor is in communication with appropriate control elements of the devices and is configured to control such elements in a manner such that the programmed instructions are carried out by the appropriate device. It will be understood that a computer readable medium programmed with instructions that cause a sensor device, blood fluid removal device, or other suitable device to carry out a method, or a portion thereof, as described herein are contemplated. The computer readable medium may be non-transitory, i.e. lasting for more than a fleeting instant or seconds. The medium may be memory, such as RAM or ROM, a cd or dvd, flash memory, or the like.


A variety of aspects of methods, systems, devices, computer-readable media and the like are disclosure herein. A summary of some of the aspects is provided below.


In a first aspect, a system comprises: (a) a blood fluid removal device comprising (i) an inlet for receiving blood from a patient, (ii) an outlet for returning blood from the patient, (iii) a medium for removing fluid and contaminants from the blood, the medium being positioned between the inlet and the first outlet, and (iv) a fluid source for carrying a fluid, the fluid selected from dialysate and replacement fluid, wherein if the fluid is dialysate the fluid source carries the fluid to the medium, and wherein if the fluid is replacement fluid the fluid source carries the fluid to the blood after the blood exits the medium; (b) a concentrate source for housing a concentrate solution comprising concentrated electrolyte or pH buffer; (c) a concentrate flow control element for controlling the rate that the concentrate solution enters the fluid source; (d) a first sensor configured to monitor an indicator of blood electrolyte concentration or blood pH; and (e) control electronics in operable communication with the sensor and the concentrate flow control element, wherein the control electronics are configured, via the concentrate flow control element, to adjust the rate at which the concentrate solution enters the fluid source based on data obtained from the sensor.


A second aspect is a system of the first aspect, wherein the first sensor is configured to monitor blood before the blood enters the medium.


A third aspect is a system of the second aspect, further comprising a second sensor configured to monitor an indicator of blood electrolyte concentration or blood pH, the second sensor being configured to monitor blood after the blood exits the medium.


A fourth aspect is a system of the third aspect, wherein the control electronics are in operable communication with the second sensor and are configured to compare data acquired from the first sensor to data acquired from the second sensor, and wherein the control electronics are configured to adjust the rate at which the concentrate solution enters the fluid source based on the comparison of the data acquired from the first sensor and the second sensor.


A fifth aspect is a system of aspect 1, wherein the first sensor is configured to monitor the indicator in fluid removed from the blood after the fluid removed from the blood exits the medium


A sixth aspect is a system of aspect 5, wherein the control electronics are configured to derive the blood pH or blood electrolyte concentration based on data acquired from the first sensor.


A seventh aspect is a system of aspect 5, further comprising a second sensor configured to monitor the indicator in dialysate in the fluid source before the dialysate enters the medium, wherein the control electronics are control electronics are in operable communication with the second sensor and are configured to compare data acquired from the first sensor to data acquired from the second sensor, and wherein the control electronics are configured to adjust the rate at which the concentrate solution enters the fluid source based on the comparison of the data acquired from the first sensor and the second sensor.


An eighth aspect is a system of the first aspect, wherein the first sensor is configured to monitor the indicator in the blood after the blood exits the medium and before replacement fluid is added to the blood.


A ninth aspect is a system of aspect 8, further comprising a second sensor configured to monitor the indicator in the blood after the replacement fluid has been added to the blood.


A tenth aspect is a system of any of aspects 1-9, wherein the control electronics, or components thereof, are housed within a housing of the blood fluid removal device.


An eleventh aspect is a system of any of aspects 1-10, further comprising a computer readable medium, wherein the computer readable medium comprises instructions that cause the control electronics to control the concentrate flow control element to adjust the rate at which the concentrate solution enters the fluid source based on data obtained from the sensor.


A twelfth aspect is a method carried out by a blood fluid removal device or system, comprising: (i) initiating blood fluid removal procedure for a patient in need thereof, wherein the procedure comprise use of a fluid selected from a dialysate fluid or a replacement fluid, and wherein the fluid has an initial pH buffer composition or electrolyte composition; (ii) monitoring an indicator of blood electrolyte concentration or blood pH of the patient during the blood fluid removal session; and (iii) adjusting the pH buffer composition or the electrolyte composition of the fluid based on a value of the monitored indicator.


A thirteenth aspect is method of aspect 12, wherein monitoring the indicator comprises monitoring the indicator in blood before passing the blood through a blood fluid removal medium and after passing the blood through the blood fluid removal medium


A fourteenth aspect is a method of aspect 13, further comprising comparing a value of the indicator monitored before the blood is passed through the medium to a value of the indicator monitored after passing the blood through the medium, wherein adjusting the pH buffer composition or the electrolyte composition comprises adjusting the composition based on the comparison.


A fifteenth aspect is a method of any of aspects 12-14, wherein adjusting the composition comprises adding a concentrated electrolyte solution or buffer solution to the fluid.


A sixteenth aspect is a method of any of aspects 12-15, further comprising (i) determining whether a value of the monitored indicator crosses a threshold; and (ii) providing an alert if the value of the monitored indicator is determined to cross the threshold.


A seventeenth aspect is a method of aspect 12, wherein monitoring the indicator comprises monitoring the indicator in fluid removed from the blood.


An eighteenth aspect is a method of aspect 17, further comprising determining a blood electrolyte concentration or pH from a value of the monitored indicator of the fluid removed from the blood.


A nineteenth aspect is a method of aspect 17 or aspect 18, wherein the fluid for use in the blood fluid removal procedure is dialysate, and wherein monitoring the indicator further comprises monitoring the indicator in the dialysate prior to the dialysate entering a blood fluid removal medium, and wherein the method further comprises comparing a value of the monitored indicator in fluid removed from the blood to a value of the monitored indicator in the dialysate prior to entering the blood fluid removal medium.


A twentieth aspect is a method of aspect 12, wherein the fluid for use in the blood fluid removal procedure is replacement fluid, and wherein monitoring the indicator comprises monitoring the indicator in blood downstream of a blood fluid removal medium and upstream of addition of the replacement fluid to the blood.


A twenty-first aspect is a method of aspect 20, wherein monitoring the indicator further comprises monitoring the indicator in the blood downstream of the addition of the replacement fluid, wherein the method further comprises comparing a value of the monitored indicator obtained upstream of the addition of replacement fluid to a value of the monitored indicator obtained downstream of the addition of replacement fluid.


A twenty-second aspect is a system comprising: (i) a medium housing defining a major chamber; (ii) a blood flow removal membrane disposed in the housing and sealingly dividing the major chamber into first and second minor chambers; (iii) a first inlet and a first outlet in fluid communication with the first minor chamber, wherein the system is configured such that blood enters the first minor chamber through the first inlet and exits the first minor chamber through the first outlet; (iv) a second inlet and a second outlet in fluid communication with the second minor chamber, wherein the system is configured such that dialysate enters the second minor chamber through the second inlet and exits the second minor chamber through the second outlet; (v) a dialysate regeneration medium in fluid communication with and disposed in a dialysate flow path between the second inlet and the second outlet; (vi) a concentrate source for housing a concentrate solution comprising concentrated electrolyte or pH buffer; (vii) a concentrate flow control element for controlling the rate that the concentrate solution enters the dialysate flow path downstream of the dialysate regeneration medium and upstream of the second inlet; (viii) a sensor configured to monitor an indicator of electrolyte concentration or pH of dialysate in the dialysate flow path downstream of the dialysate regeneration medium and upstream of the second inlet; and (ix) control electronics in operable communication with the sensor and the concentrate flow control element, wherein the control electronics are configured, via the concentrate flow control element, to adjust the rate at which the concentrate solution enters the dialysate flow path based on data obtained from the sensor.


A twenty-third aspect is a method carried out by a blood fluid removal device or system, comprising: (i) initiating blood fluid removal procedure for a patient in need thereof, wherein the procedure comprises use of a dialysate fluid and a dialysate membrane, as at least a part of a blood fluid removal medium, across which electrolytes may be exchanged between blood and the dialysate fluid; (ii) monitoring an indicator of blood electrolyte concentration or blood pH during the blood fluid removal session; and (iii) adjusting the flow rate of the dialysate fluid or blood based on a value of the monitored indicator.


A twenty-fourth aspect is a method of aspect 23, wherein monitoring the indicator comprises monitoring the indicator in blood before passing the blood through the blood fluid removal medium and after passing the blood through the blood fluid removal medium.


A twenty-fifth aspect is a method of aspect 23, further comprising comparing a value of the indicator monitored before the blood is passed through the medium to a value of the indicator monitored after passing the blood through the medium, wherein adjusting the flow rate of the dialysate fluid or the blood comprises adjusting the composition based on the comparison.


A twenty-sixth aspect is a method of any of aspects 23-25, wherein monitoring the indicator comprises monitoring the indicator in fluid removed from the blood.


A twenty-seventh aspect is a method of aspect 23, further comprising determining a blood electrolyte concentration or pH from a value of the monitored indicator of the fluid removed from the blood.


Thus, systems, devices and methods for ELECTROLYTE AND pH MONITORING FOR FLUID REMOVAL PROCESSES are described. Those skilled in the art will recognize that the preferred embodiments described herein may be altered or amended without departing from the true spirit and scope of the disclosure, as defined in the accompanying claims.


In the claims that follow, the designators “first”, “second”, “third” and the like are used for purposes of distinguishing between elements and not for purposes of enumerating the elements or for defining a sequence of the elements. For example, a “third” sensor does not necessarily imply that there are three sensors but rather that the “third” sensor is distinct from the “first” sensor. By way of further example, a “third” sensor does not necessarily come later in time than a “first” sensor.

Claims
  • 1. A system comprising: a blood fluid removal device comprising:(i) an inlet for receiving blood from a patient,(ii) an outlet for returning blood from the patient,(iii) a medium for removing fluid and contaminants from the blood, the medium being positioned between the inlet and the outlet, and(iv) a fluid line for carrying fluid to the medium;a concentrate source for housing a concentrate solution comprising concentrated electrolyte or pH buffer;a concentrate flow control element for controlling the rate that the concentrate solution enters the fluid line;a first sensor configured to monitor an indicator of electrolyte concentration or pH in dialysate in the fluid line before the dialysate enters the medium;a second sensor configured to monitor an indicator of electrolyte concentration or pH in the dialysate in the fluid line after the dialysate exits the medium; andcontrol electronics in operable communication with the first sensor and the concentrate flow control element,wherein the control electronics are configured, via the concentrate flow control element, to adjust the rate at which the concentrate solution enters the fluid line based on a rate of change of blood electrolyte level or blood pH based on data obtained from the first sensor and the second sensor.
  • 2. The system of claim 1, wherein the data obtained from the first sensor and the second sensor is used to predict blood electrolyte concentration or blood pH.
  • 3. The system of claim 1, wherein the control electronics are configured, via the concentrate flow control element, to adjust the rate at which the concentrate solution enters the fluid line based on a comparison of the data received from the first sensor and the data received from the second sensor.
  • 4. The system of claim 1, further comprising a dialysate regeneration system, wherein the first sensor is configured to monitor the indicator of electrolyte concentration or pH in the dialysate in the fluid line after the dialysate exits the regeneration system, and wherein the second sensor is configured to monitor the indicator of electrolyte concentration or pH in the dialysate in the fluid line before the dialysate enters the regeneration system.
  • 5. The system of claim 4, wherein the concentrate solution enters the fluid line after the dialysate exits the dialysate regeneration system.
  • 6. The system of claim 1, wherein the first sensor is configured to monitor the indicator of electrolyte concentration or pH in the dialysate in the fluid line after the concentrate solution enters the fluid line.
  • 7. The system of claim 1, further comprising a third sensor configured to monitor the indicator in the blood after the blood exits the medium.
  • 8. The system of claim 1, wherein the control electronics are configured to adjust a rate at which dialysate enters the medium or the rate at which blood enters the medium based on data obtained from the first sensor and the second sensor.
  • 9. The system of claim 1, wherein the control electronics, or components thereof, are housed within a housing of the blood fluid removal device.
  • 10. A method carried out by the system of claim 1, comprising: initiating a blood fluid removal procedure, wherein the procedure comprises use of a dialysate with an initial pH buffer composition or electrolyte composition;monitoring an indicator of pH or electrolyte concentration in the dialysate during the blood fluid removal session; andadjusting the pH buffer composition or the electrolyte composition of the dialysate based on a value of the monitored indicator.
  • 11. The method of claim 10, wherein the indicator of pH or electrolyte concentration in the dialysate is monitored after the dialysate exits a blood fluid removal medium and wherein the indicator of pH or electrolyte concentration in the dialysate is monitored before the dialysate enters the blood fluid removal medium.
  • 12. The method of claim 11, wherein the pH buffer composition or electrolyte composition of the dialysate is adjusted based on a blood electrolyte concentration or blood pH, based on the indicator of pH or electrolyte concentration in the dialysate after the dialysate exits a blood fluid removal medium and the indicator of pH or electrolyte concentration in the dialysate before the dialysate enters the blood fluid removal medium.
  • 13. The method of claim 12, wherein adjusting the pH buffer composition or electrolyte composition comprises adding a concentrate electrolyte solution or concentrated buffer solution to the dialysate.
  • 14. The method of claim 10, further comprising: determining whether a value of the monitored indicator crosses a threshold; andproviding an alert if the value of the monitored indicator crosses the threshold.
  • 15. The method of claim 11, further comprising deriving a blood electrolyte concentration or blood pH from the monitored indicator before the dialysate enters the medium and after the dialysate exits the medium.
  • 16. The method of claim 11, further comprising monitoring the indicator in blood after the blood exits the blood fluid removal medium.
  • 17. The method of claim 11, further comprising adjusting a rate at which dialysate enters the blood fluid removal medium or a rate at which blood enters the blood fluid removal medium based on the monitored indicator.
  • 18. The method of claim 11, wherein the dialysate is regenerated with a dialysate regeneration system, and wherein the indicator of pH or electrolyte concentration in the dialysate is monitored after the dialysate exits the blood fluid removal medium but before the dialysate enters the dialysate regeneration system; and wherein the indicator of pH or electrolyte concentration in the dialysate is monitored after the dialysate exits the dialysate regeneration system but before the dialysate enters the blood fluid removal medium.
  • 19. The method of claim 18, wherein adjusting the pH buffer composition or electrolyte composition comprises adding a concentrated electrolyte solution or concentrated buffer solution to the dialysate after the dialysate has been regenerated.
  • 20. The method of claim 19, wherein the pH or electrolyte concentration in the dialysate is monitored after the concentrated electrolyte solution or concentrated buffer solution has been added to the dialysate.
RELATED APPLICATION

This application claims priority as a continuation application to U.S. application Ser. No. 13/424,479, filed on Mar. 20, 2012, which in turn claims priority to U.S. Provisional Application No. 61/480,539, U.S. Provisional Application No. 61/480,544, U.S. Provisional Application No. 61/480,541, U.S. Provisional Application No. 61/480,535, U.S. Provisional Application No. 61/480,532, U.S. Provisional Application No. 61/480,530, and U.S. Provisional Application No. 61/480,528, wherein each provisional application was filed Apr. 29, 2011, and wherein each provisional application is hereby incorporated by reference in its entirety to the extent that it does not conflict with the disclosure presented herein.

US Referenced Citations (263)
Number Name Date Kind
3608729 Haselden Sep 1971 A
3669878 Marantz Jun 1972 A
3669880 Marantz Jun 1972 A
3850835 Marantz Nov 1974 A
3884808 Scott May 1975 A
3989622 Marantz Nov 1976 A
4060485 Eaton Nov 1977 A
4371385 Johnson Feb 1983 A
4374382 Markowitz Feb 1983 A
4381999 Boucher May 1983 A
4460555 Thompson Jul 1984 A
4556063 Thompson Dec 1985 A
4562751 Nason Jan 1986 A
4581141 Ash Apr 1986 A
4650587 Polak Mar 1987 A
4678408 Mason Jul 1987 A
4685903 Cable Aug 1987 A
4750494 King Jun 1988 A
4826663 Alberti May 1989 A
4828693 Lindsay May 1989 A
5080653 Voss Jan 1992 A
5092886 Dobos-Hardy Mar 1992 A
5097122 Coiman Mar 1992 A
5127404 Wyborny Jul 1992 A
5284470 Beltz Feb 1994 A
5302288 Meidl Apr 1994 A
5305745 Zacouto Apr 1994 A
5318750 Lascombes Jun 1994 A
5468388 Goddard Nov 1995 A
5507723 Keshaviah Apr 1996 A
5651893 Kenley Jul 1997 A
5683432 Goedeke Nov 1997 A
5744031 Bene Apr 1998 A
5762782 Kenley Jun 1998 A
5902336 Mishkin May 1999 A
5944684 Roberts Aug 1999 A
6048732 Anslyn Apr 2000 A
6052622 Holmstrom Apr 2000 A
6058331 King May 2000 A
6156002 Polaschegg Dec 2000 A
6230059 Duffin May 2001 B1
6248093 Moberg Jun 2001 B1
6254567 Treu Jul 2001 B1
6321101 Holmstrom Nov 2001 B1
6362591 Moberg Mar 2002 B1
6363279 Ben-Haim Mar 2002 B1
6505075 Weiner Jan 2003 B1
6554798 Mann Apr 2003 B1
6555986 Moberg Apr 2003 B2
6589229 Connelly Jul 2003 B1
6602399 Fromherz Aug 2003 B1
6627164 Wong Sep 2003 B1
6676608 Keren Jan 2004 B1
6689083 Gelfand Feb 2004 B1
6706007 Gelfand Mar 2004 B2
6711439 Bradley Mar 2004 B1
6726647 Sternby Apr 2004 B1
6780322 Bissler Aug 2004 B1
6818196 Wong Nov 2004 B2
6878283 Thompson Apr 2005 B2
6887214 Levin May 2005 B1
6890315 Levin May 2005 B1
6960179 Gura Nov 2005 B2
7074332 Summerton Jul 2006 B2
7077819 Goldau Jul 2006 B1
7131956 Pirazzoli Nov 2006 B1
7175809 Gelfand Feb 2007 B2
7208092 Micheli Apr 2007 B2
7276042 Polaschegg Oct 2007 B2
7399289 Gelfand Jul 2008 B2
7500958 Asbrink Mar 2009 B2
7575564 Childers Aug 2009 B2
7674231 McCombie Mar 2010 B2
7704361 Garde Apr 2010 B2
7736507 Wong Jun 2010 B2
7744553 Kelly Jun 2010 B2
7754852 Burnett Jul 2010 B2
7756572 Fard Jul 2010 B1
7775983 Zhang Aug 2010 B2
7776210 Rosenbaum Aug 2010 B2
7785463 Bissler Aug 2010 B2
7794141 Perry Sep 2010 B2
7850635 Polaschegg Dec 2010 B2
7857976 Bissler Dec 2010 B2
7867214 Childers Jan 2011 B2
7896831 Sternby Mar 2011 B2
7922686 Childers Apr 2011 B2
7922911 Micheli Apr 2011 B2
7947179 Rosenbaum May 2011 B2
7955291 Sternby Jun 2011 B2
7967022 Grant Jun 2011 B2
7981082 Wang Jul 2011 B2
8000000 Greenberg Aug 2011 B2
8034161 Gura Oct 2011 B2
8070709 Childers Dec 2011 B2
8096969 Roberts Jan 2012 B2
8105260 Tonelli Jan 2012 B2
8183046 Lu May 2012 B2
8187250 Roberts May 2012 B2
8197439 Wang Jun 2012 B2
8202241 Karakama Jun 2012 B2
8246826 Wilt Aug 2012 B2
8273049 Demers Sep 2012 B2
8282828 Wallenas Oct 2012 B2
8292594 Tracey Oct 2012 B2
8313642 Yu Nov 2012 B2
8317492 Demers Nov 2012 B2
8357113 Childers Jan 2013 B2
8366316 Kamen Feb 2013 B2
8366655 Kamen Feb 2013 B2
1383728 Pudil Mar 2013 A1
8404091 Ding Mar 2013 B2
8409441 Wilt Apr 2013 B2
8496809 Roger Jul 2013 B2
8499780 Wilt Aug 2013 B2
8500676 Jansson Aug 2013 B2
8512271 Moissl Aug 2013 B2
8518260 Raimann Aug 2013 B2
8521482 Akonur Aug 2013 B2
8535525 Heyes Sep 2013 B2
8560510 Brueggerhoff Oct 2013 B2
8580112 Updyke Nov 2013 B2
8597227 Childers Dec 2013 B2
8696626 Kirsch Apr 2014 B2
8903492 Soykan Dec 2014 B2
8926542 Gerber Jan 2015 B2
20020042561 Schulman Apr 2002 A1
20020112609 Wong Aug 2002 A1
20030080059 Peterson May 2003 A1
20030097086 Gura May 2003 A1
20030105435 Taylor Jun 2003 A1
20030114787 Gura Jun 2003 A1
20040019312 Childers Jan 2004 A1
20040068219 Summerton Apr 2004 A1
20040099593 DePaolis May 2004 A1
20040147900 Polaschegg Jul 2004 A1
20040168969 Sternby Sep 2004 A1
20040215090 Erkkila Oct 2004 A1
20050065760 Murtfeldt Mar 2005 A1
20050113796 Taylor May 2005 A1
20050126961 Bissler Jun 2005 A1
20050131331 Kelly Jun 2005 A1
20050126998 Childers Jul 2005 A1
20050150832 Tsukamoto Jul 2005 A1
20050234381 Niemetz Oct 2005 A1
20050236330 Nier Oct 2005 A1
20050274658 Rosenbaum Dec 2005 A1
20060025661 Sweeney Feb 2006 A1
20060217771 Soykan Feb 2006 A1
20060058731 Burnett Mar 2006 A1
20060195064 Plahey Aug 2006 A1
20060226079 Mori Oct 2006 A1
20060241709 Soykan Oct 2006 A1
20060264894 Moberg Nov 2006 A1
20070007208 Brugger Jan 2007 A1
20070066928 Lannoy Mar 2007 A1
20070138011 Hofmann Jun 2007 A1
20070175827 Wariar Aug 2007 A1
20070179431 Roberts Aug 2007 A1
20070213653 Childers Sep 2007 A1
20070215545 Bissler Sep 2007 A1
20070255250 Moberg Nov 2007 A1
20080006570 Gura Jan 2008 A1
20080021337 Li Jan 2008 A1
20080053905 Brugger Mar 2008 A9
20080067132 Ross Mar 2008 A1
20080093276 Roger Apr 2008 A1
20080215247 Tonelli Sep 2008 A1
20080253427 Kamen Oct 2008 A1
20090020471 Tsukamoto Jan 2009 A1
20090101577 Fulkerson Apr 2009 A1
20090124963 Hogard May 2009 A1
20090127193 Updyke May 2009 A1
20090171261 Sternby Jul 2009 A1
20090264776 Vardy Oct 2009 A1
20090275849 Stewart Nov 2009 A1
20090275883 Chapman Nov 2009 A1
20090281484 Childers Nov 2009 A1
20090282980 Gura Nov 2009 A1
20090314063 Sternby Dec 2009 A1
20100004588 Yeh Jan 2010 A1
20100010429 Childers Jan 2010 A1
20100042035 Moissl Feb 2010 A1
20100076398 Scheurer Mar 2010 A1
20100078381 Merchant Apr 2010 A1
20100078387 Wong Apr 2010 A1
20100084330 Wong Apr 2010 A1
20100087771 Karakama Apr 2010 A1
20100094158 Solem Apr 2010 A1
20100113891 Barrett May 2010 A1
20100114012 Sandford May 2010 A1
20100137693 Porras Jun 2010 A1
20100137782 Jansson Jun 2010 A1
20100168546 Kamath Jul 2010 A1
20100217180 Akonur Aug 2010 A1
20100217181 Roberts Aug 2010 A1
20100224492 Ding Sep 2010 A1
20100234795 Wallenas Sep 2010 A1
20100241045 Kelly Sep 2010 A1
20100264086 Noack Oct 2010 A1
20110017665 Updyke Jan 2011 A1
20110048949 Ding et al. Mar 2011 A1
20110066043 Banet Mar 2011 A1
20110071465 Wang Mar 2011 A1
20110077574 Sigg Mar 2011 A1
20110079558 Raimann Apr 2011 A1
20110087187 Beck Apr 2011 A1
20110100909 Stange May 2011 A1
20110106003 Childers May 2011 A1
20110130666 Dong Jun 2011 A1
20110144570 Childers Jun 2011 A1
20110184340 Tan Jul 2011 A1
20110208105 Brandl Aug 2011 A1
20110272337 Palmer Nov 2011 A1
20110301447 Park Dec 2011 A1
20120016228 Kroh Jan 2012 A1
20120083729 Childers Apr 2012 A1
20120085707 Beiriger Apr 2012 A1
20120115248 Ansyln May 2012 A1
20120220528 VanAntwerp Aug 2012 A1
20120258546 Marran Oct 2012 A1
20120259276 Childers Oct 2012 A1
20120273415 Gerber Nov 2012 A1
20120273420 Gerber Nov 2012 A1
20120277546 Soykan Nov 2012 A1
20120277551 Gerber Nov 2012 A1
20120277552 Gerber Nov 2012 A1
20120277604 Gerber Nov 2012 A1
20120277650 Gerber Nov 2012 A1
20120277655 Gerber Nov 2012 A1
20120277722 Gerber Nov 2012 A1
20130037465 Heyes Feb 2013 A1
20130062265 Balschat Mar 2013 A1
20130193073 Hogard Aug 2013 A1
20130199998 Kelly Aug 2013 A1
20130211730 Wolff Aug 2013 A1
20130213890 Kelly Aug 2013 A1
20130228517 Roger Sep 2013 A1
20130231607 Roger Sep 2013 A1
20130248426 Pouchoulin Sep 2013 A1
20130274642 Soykan Oct 2013 A1
20130324915 (Krensky)Britton Dec 2013 A1
20130330208 Ly Dec 2013 A1
20130331774 Farrell Dec 2013 A1
20140018728 Plahey Jan 2014 A1
20140042092 Akonur Feb 2014 A1
20140088442 Soykan Mar 2014 A1
20140110340 White Apr 2014 A1
20140110341 White Apr 2014 A1
20140158538 Collier Jun 2014 A1
20140158588 Pudil Jun 2014 A1
20140158623 Pudil Jun 2014 A1
20140190876 Meyer Jul 2014 A1
20140217029 Meyer Aug 2014 A1
20140220699 Pudil Aug 2014 A1
20150032023 Soykan Jan 2015 A1
20150080682 Gerber Mar 2015 A1
20150088047 Gerber Mar 2015 A1
20150250427 Soykan Sep 2015 A1
20150352269 Gerber Dec 2015 A1
20150367054 Gerber Dec 2015 A1
20160206801 Gerber Jul 2016 A1
20160331884 Sigg Nov 2016 A1
Foreign Referenced Citations (112)
Number Date Country
0101193667 Jun 2008 CN
103037917 Apr 2013 CN
266795 Nov 1987 EP
0272414 Oct 1991 EP
0330892 Jul 1994 EP
1124599 May 2000 EP
1175238 Nov 2000 EP
2308526 Oct 2003 EP
1364666 Nov 2003 EP
1523347 Jan 2004 EP
1523350 Jan 2004 EP
0906768 Feb 2004 EP
1691863 Apr 2005 EP
2116269 Feb 2008 EP
1450879 Oct 2008 EP
1514562 Apr 2009 EP
2219703 May 2009 EP
1592494 Jun 2009 EP
2100553 Sep 2009 EP
2398529 Nov 2010 EP
2575827 Dec 2010 EP
2576453 Dec 2011 EP
2701580 Nov 2012 EP
2701595 Nov 2012 EP
1345856 Mar 2013 EP
2344220 Apr 2013 EP
1351756 Jul 2013 EP
2190498 Jul 2013 EP
2701596 Mar 2014 EP
1582226 Jan 2016 EP
S63-143077 Nov 1987 JP
2002533170 Oct 2002 JP
2002542900 Dec 2002 JP
2003235965 Aug 2003 JP
2005-533573 Nov 2005 JP
5099464 Oct 2012 JP
1995003839 Feb 1995 WO
9937342 Jul 1999 WO
0057935 Oct 2000 WO
2000066197 Nov 2000 WO
2001085295 Sep 2001 WO
0185295 Nov 2001 WO
1085295 Nov 2001 WO
200066197 Nov 2001 WO
2002013691 Feb 2002 WO
2003043677 May 2003 WO
2003043680 May 2003 WO
2003051422 Jun 2003 WO
2004008826 Jan 2004 WO
2004009156 Jan 2004 WO
2004009158 Jan 2004 WO
200170307 Apr 2004 WO
2004030716 Apr 2004 WO
2004030717 Apr 2004 WO
2004064616 Aug 2004 WO
2005061026 Jul 2005 WO
2005123230 Dec 2005 WO
2006011009 Feb 2006 WO
2006017446 Feb 2006 WO
2007038347 Apr 2007 WO
2007089855 Aug 2007 WO
2008037410 Apr 2008 WO
2009026603 Dec 2008 WO
2009024566 Feb 2009 WO
2009026603 Mar 2009 WO
2009061608 May 2009 WO
2009094184 Jul 2009 WO
2009157877 Dec 2009 WO
2009157878 Dec 2009 WO
0210028860 Mar 2010 WO
2010024963 Mar 2010 WO
2010028860 Mar 2010 WO
2010033314 Mar 2010 WO
2010033699 Mar 2010 WO
2010077851 Jul 2010 WO
2010096659 Oct 2010 WO
2010121820 Oct 2010 WO
2011025705 Mar 2011 WO
2011026645 Mar 2011 WO
2011137693 Nov 2011 WO
2012042323 Apr 2012 WO
2012050781 Apr 2012 WO
2012051996 Apr 2012 WO
2012073420 Jul 2012 WO
12148786 Nov 2012 WO
12148789 Nov 2012 WO
2012148781 Nov 2012 WO
2012148787 Nov 2012 WO
2012148789 Nov 2012 WO
2012162515 Nov 2012 WO
2012172398 Dec 2012 WO
2013019179 Feb 2013 WO
2013019994 Feb 2013 WO
2013025844 Feb 2013 WO
2013028809 Feb 2013 WO
2013101292 Jul 2013 WO
2013103607 Jul 2013 WO
2013103906 Jul 2013 WO
2013110906 Aug 2013 WO
2013110919 Aug 2013 WO
2013114063 Aug 2013 WO
2013121162 Aug 2013 WO
2013140346 Sep 2013 WO
2013141896 Sep 2013 WO
2013101292 Oct 2013 WO
14066254 May 2014 WO
14066255 May 2014 WO
14077082 May 2014 WO
2014121162 Aug 2014 WO
2014121163 Aug 2014 WO
2014121167 Aug 2014 WO
2014121169 Aug 2014 WO
Non-Patent Literature Citations (48)
Entry
PCT/US2012/034335, International Preliminary Report on Patentability, dated Nov. 7, 2013.
PCT/US2012/034329, International Preliminary Report on Patentability, dated Oct. 29, 2013.
U.S. Appl. No. 13/837,287, filed Mar. 15, 2013.
Bleyer, et. al., Sudden and cardiac death rated in hemodialysis patients, Kidney International. 1999, 1553-1559: 55.
U.S. Appl. No. 13/424,517, IDS filed Dec. 2, 2013.
PCT/US2012/034327, International Preliminary Report on Patentability, dated Oct. 29, 2013.
Zoccali, Pulmonary Congestion Predicts Cardiac Events and Mortality in ESRD, Clinical Epidemiology, J. Am Soc Nephrol 24:639-646, 2013.
Velasco, Optimal Fluid Control can Normalize Cardiovascular Risk Markers and Limit Left Ventricular Hypertrophy in Thrice Weekly Dialysis Patients, Hemodialysis Intenational, 16:465-472, 2012.
Whitman, CKD and Sudden Cardiac Death: Epidemiology, Mechanisms, and Therapeutic Approaches, J Am Soc Nephrol, 23:1929-1939, 2012.
Hall, Hospitalization for Congestive Heart Failure: United States, 2000-2010, NCHS Data Brief, No. 108, Oct. 2012.
Albert, Fluid Management Strategies in Heart Failure, Critical Care Nurse, 32:20-32, 2012.
PCT/US2014/065201 International Search Report dated May 26, 2015.
John Wm Agar: “Review: Understanding sorbent dialysis systems,” Nephrology, vol. 15, No. 4, Jun. 1, 2010, pp. 406-411.
Office Action in Chinese Application No. 201510511657.9 dated Dec. 28, 2016.
Office Action in Chinese Application No. 201280020932.1 dated Jan. 7, 2015.
Office Action in Chinese Application No. 201280020932.1 dated Apr. 3, 2015.
PCT/US2012/034330, International Search Report and Written Opinion dated Aug. 28, 2012.
Office Action in Chinese Application No. 201510593695.3 dated Jul. 12, 2017.
Office Action in Chinese Application No. 201510511657.9 dated May 10, 2017.
Office Action in European Application No. EP 12717021.5 dated Feb. 3, 2017.
Bleyer, et. al., Sudden and cardiac death rates in hemodialysis patients, Kidney International, 1999, 1553-1559 : 55.
ISA Invitation to Pay Additional Fees, PCT/US2012/034323 dated Aug. 2, 2012.
MacLean, et, al., Effects of hindlimb contraction on pressor and muscle interstitial metabolite responses in the cat, J. App. Physiol., 1998, 1583-1592, 85(4).
PCT/US2012/034330, International Search Report, dated Aug. 28, 2012.
PCT/US2012/034332, International Search Report, dated Jul. 5, 2012.
Roberts M, The regenerative dialysis (REDY) sorbent system. Nephrology, 1998, 275-278:4.
Ronco, et. al., “Cardiorenal Syndrome”, J. Am. Coll. Cardiol., 2008, 1527-1539: 52.
Wang, Fundamentals of intrathoracic impedance monitoring in heart failure, Am. J. Cardiology, 2007, 3G-10G : Suppl.
Weiner, et. al., Article: Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease, Book: Primer on Kidney Diseases (Author: Greenberg, et al), 2009,499-505, 5th Ed., Saunders Elsevier, Philadelphia, PA.
Wang, Fundamentals of intrathoracic impedance monitoring in heart failure, Am. J. Cardiology, 2007, 3G-310: Suppl.
Brynda, et. al., The detection of toman 2-microglcbuiin by grating coupler immunosensor with three dimensional antibody networks. Biosensors & Bioelectronics, 1999, 363-368, 14(4).
Hemametrics, Crit-Line Hematocrit Accuracy, 2003, 1-5, vol. 1, Tech Note No. 11 (Rev. D).
Nedelkov, et. al., Design of buffer exchange surfaces and sensor chips for biosensor chip mass spectrometry, Proteomics, 2002, 441-446, 2(4).
PCT/US/2012/034327, International Search Report, dated Aug. 13, 2013.
PCT/US/2012/034329, International Search Report, dated Dec. 3, 2012.
PCT/US2012/034331, International Search Report, dated Jul. 9, 2012.
PCT/US2012/034334, International Search Report, dated Jul. 6, 2012.
PCT/US2012/034335, International Search Report, dated Sep. 5, 2012.
Rogoza, et. al., Validation of A&D UA-767 device for the self-measurement of blood pressure, Blood Pressure Monitoring, 2000, 227-231, 5(4).
Secemsky, et. al, High prevalence of cardiac autonomic dysfunction and T-wave alternans in dialysis patients. Heart Rhythm, Apr. 2011, 592-598 : vol. 8, No. 4.
Wei, et. al., Fullerene-cryptand coated piezoelectric crystal urea sensor based on urease, Analytica Chimica Acta, 2001,77-85:437.
Zhong, et. al., Miniature urea sensor based on H(+)-ion sensitive field effect transistor and its application in clinical analysis, Chin. J. Biotechnol., 1992, 57-65. 8(1).
The FHN Trial Group. In-Center. Hemodialysis Six Times per Week versus Three Times per Week, New England Journal of Medicine, 2010.
Coast, et al. 1990, An approach to Cardiac Arrhythmia analysis Using Hidden Markov Models, IEEE Transactions on Biomedical Engineering. 1990, 37 (9):826-835.
PCT/US2012/034330, International Preliminary Report on Patentability, dated Oct. 29, 2013.
PCT Application, PCT/US20013/020404, filed Jan. 4, 2013.
PCT/US2012/034333, International Preliminary Report on Patentability, dated Oct. 29, 2013.
PCT/US2012/034333, International Search Report, dated Aug. 29, 2013.
Related Publications (1)
Number Date Country
20150352269 A1 Dec 2015 US
Provisional Applications (7)
Number Date Country
61480539 Apr 2011 US
61480544 Apr 2011 US
61480541 Apr 2011 US
61480535 Apr 2011 US
61480532 Apr 2011 US
61480530 Apr 2011 US
61480528 Apr 2011 US
Continuations (1)
Number Date Country
Parent 13424479 Mar 2012 US
Child 14828979 US